Good MorningEquities fell on Thursday in response to rocketing interest rate expectations. The NASDAQ led the decline with a loss near 3.0% while the S&P 500 and Dow Jones shed less than half that amount. The yield on the ten-year treasury jumped above 1.70% for the first time since January 2020 and it looks like it will go higher. This is bad news for high-growth names because it makes borrowing money to fund growth more expensive and could send the NASDAQ Composite tumbling.
The next big hurdle for the market will be next week with the release of key data points. Among them are the February reads of personal income, spending, and core inflation. If core inflation continues on its upward trajectory it could reinforce the idea of FOMC tightening and help drive the markets lower over the coming months
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Discretionary | |
Even though you might be thinking that housing activity is cooling down a bit after a big run over the last year, there’s still plenty of reasons to believe that the homebuilders are great stocks to own at this time. Although things like rising lumber costs and higher interest rates should n... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
If my headline confuses you, then you’re probably thinking clearly about Sundial Growers (NASDAQ:SNDL). The cannabis stock has been the target of attention from retail investors. SNDL stock has charged ahead 180% after getting the GameStop (NYSE:GME) treatment. But the stock has fallen about... Read the Full Story |
|
Consumer Discretionary | | California-based electric vehicle (EV) manufacturer Canoo Holdings Ltd. (NASDAQ: GOEV) stock has been selling off after it completed its reverse merger business combination with Hennessy Capital Corporation. The new symbol change went into effect on Dec. 22, 2020. As with most special-purpose-acquis... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Industrials | | Solar energy solutions provider SunPower (NASDAQ: SPWR) stock has been a pandemic winner in 2020 hitting multi-year highs of $57.52 in January 2021 before plummeting by more than half to lows of $27.39 by March. The Company entered the year on the heels of the powerful clean and renewable energy the... Read the Full Story |
|
Consumer Discretionary | |
In sharp contrast to much of the last ten years, value appears to be in and growth out. With the performance of value stocks distancing itself from that of growth stocks in recent weeks, many investors are scrambling to reposition their portfolios to have more of a value bent.
Many value stocks h... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Markets | | Exodus Movement, Inc Files With SEC For Regulation A IPO
The Exodus Wallet is on the verge of making history with its planned IPO and we know that is saying a lot. There have been no few history-making IPO’s over the last few years and that’s not even mentioning the SPAC craze or even ... Read the Full Story |
|
Industrials | |
FedEx Corporation Confirms Price Reversal
Shares of FedEx (NYSE:FDX) are up more than 5% in premarket trading because the company is proving its value to investors. Perfectly situation for the pandemic as a go-to logistics service for eCommerce portals of all variety, FedEx used those tailwinds ... Read the Full Story |
|
Industrials | |
Cintas Is The Best-In-Breed Play On Labor Market Strength
There are lots of ways to play the labor market but Cintas (NASDAQ: CTAS) is by far the best in the breed. The only problem with the stock is that is the best in the breed which means you pay a lot for what you get. The 35X earnings the ... Read the Full Story |
|
Consumer Discretionary | |
A year ago, going out to eat at a restaurant was an activity met with serious concern. With so many question marks about the pandemic and widespread efforts to maintain social distance, many of these businesses were put through the wringer and saw sharp declines in sales. This led investors to tak... Read the Full Story |
|
Consumer Staples | |
Both Dollar General (NYSE:DG) and Ollie’s Bargain Outlet Holdings (NASDAQ:OLLI) are trading significantly lower in the last month. And with neither stock getting a bump from earnings, it might be fair for you to wonder if the answer to the question in my headline is "are those my only choice... Read the Full Story |
|
The Early Bird Stock Of The Day Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. | | View Today's Stock Pick |
|
